Pharma & Biotech News , from our Global Correspondents
Refine Search
Generics
The Russian government plans to accelerate its efforts aimed at raising exports of domestic drugs and active ingredients by 2030, reports The Pharma Letter’s local correspondent. 6 August 2019
Pharmaceutical
The National List of Essential Medicines (NLEM) in India, which determines the basis of drug price regulation, is set to add new medicines for the treatment of cardiac diseases and cancer along with certain antibiotics to its list. This would result in a massive slash in prices for these drugs, reports The Pharma Letter’s India correspondent. 1 August 2019
Biotechnology
Russian drugmaker Biocad is expanding into the therapeutic area of psoriatic drugs, through the launch of production of its new treatment Efleira (netakimab), according to recent statements by the company, reports The Pharma Letter’s local correspondent. 29 July 2019
Pharmaceutical
Russia may become the world’s first country that will have its own production of a drug for the treatment of hepatitis Delta, according to recent statements by Pavel Bogomolov, head of the Department of Hepatology at Moscow Vladimirsky Regional Research Clinical Institute. 29 July 2019
Generics
Global drugmakers may find it easier to reach amicable agreements with their Russian rivals over patent disputes for their drugs in the local market, mainly due to a recent agreement, reached between Russian drugmaker Pharmasyntez and the Argentinian firm Laboratorio Tuteur in the patent dispute between the companies. 23 July 2019
Pharmaceutical
The Russian government is considering easing the existing restrictions on the participation of foreign drugmakers during public procurements in the domestic market, according to recent statements of some sources close to the Russian Ministry of Health and industry analysts, reports The Pharma Letter’s local correspondent. 23 July 2019
Biosimilars
As some of the world’s best-known biologics continue to face patent expiration, the biosimilars market faces a major haul of opportunities. However, though Indian firms have launched around 50 such products in the domestic market, a new report suggests certain regulatory framework concerns for biopharmaceuticals need to be addressed, reports The Pharma Letter’s India correspondent. 18 July 2019
Pharmaceutical
For investment bankers, recent M&A activity inside Japan pharma has been a non-event. No deals-no fees. Could this be a temporary lull or a harbinger of what is to come? 17 July 2019
Pharmaceutical
US pharma giant Merck & Co, known as MSD outside of the USA and Canada, will transfer the technology for the production of vaccines against chickenpox, rotavirus and human papillomavirus (HPV) to the Russian drugmaker Rostec, with the aim of a further localization of its manufacturing within the country, according to recent statements by the companies. 17 July 2019
Biosimilars
The Russian drugmaker Geropharm has officially announced the completion of registration two biosimilars of insulin lispro, particularly those of ultra-short and medium-duration action, according to the company, reports The Pharma Letter’s local correspondent. 17 July 2019
Pharmaceutical
German pharma major Bayer has confirmed its plans to localize 50% of its drugs in Russia by 2025, according to recent statements by Niels Hessmann, general representative of Bayer in Russia and the CIS region, reports The Pharma Letter’s local correspondent. 9 July 2019
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca is considering initiating massive exports of its Russian-made drugs, particularly those produced at the capacities of its local plant in the Kaluga region, according to recent statements by Leonard Wang, executive vice president of AstraZeneca International Markets and head of AstraZeneca China. 9 July 2019
Biotechnology
Myelodysplastic syndromes (MDS) are a group of disorders that arise from the inadequate functioning of the bone marrow (the spongy material in bones with stem cells), particularly in blood cell production. 9 July 2019
Biotechnology
Bispecific antibodies are artificial proteins that contain two different antigen-binding sites, allowing them to bind to two different types of antigens at the same time.1 As a result, bispecific antibodies can target several molecules, which potentially provides an advantage over utilizing combination therapies or mixtures of various antibodies, writes Dr Nicola Davies in her exclusive blog for The Pharma Letter. 8 July 2019
Pharmaceutical
A moderation in pricing pressure for the US market, new launches and market share gains for existing products along with consolidation benefits are set to drive growth for India’s pharmaceutical industry in fiscal year 2020, reports The Pharma Letter’s local correspondent. 8 July 2019
Pharmaceutical
Mexico’s pharmaceutical industry – renowned for the quality and reliability of its medicines production – sees South America and Europe as its main export markets. 8 July 2019
Pharmaceutical
The Russian government has put forward an initiative for the compulsory licensing of patented drugs produced for exports, so that Russian companies can manufacture and sell drugs protected by a patent, according to recent statements by the press service of the Russian federal government, reports The Pharma Letter’s local correspondent. 1 July 2019
Pharmaceutical
Close on the heels of an alert raised by the US Food and Drug Administration and Health Canada regarding the safety of sodium glucose cotransporter-2 (SGLT-2) inhibitors from Johnson & Johnson (NUSE: JNJ) and Germany-based Boehringer Ingelheim, the Drug Controller General of India (DCGI) has asked drug manufacturers to carry a warning label on all new diabetes drugs, reports The Pharma Letter’s India correspondent. 1 July 2019
Pharmaceutical
Global drugmakers operating in the Russian market are considering optimizing of their local ranges this year, mainly as a result of the introduction of new labeling practices in Russia, starting from January, 1 2020, and with the associated increase of their costs, reports The Pharma Letter’s local correspondent. 1 July 2019
Biotechnology
A new cholera vaccine, in Phase III trials, is expected to be six times cheaper than the three currently available in India, making it more cost-effective for inclusion in public health programs, reports The Pharma Letter’s local correspondent. 27 June 2019
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Pharmaceutical
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
Generics
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
Pharmaceutical
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Generics
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
Generics
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Pharmaceutical
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze